REGiMMUNE
PrivateLast Round
Private Equity
Sep 22, 2025
Total Funding Raised
$46M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
REGiMMUNE is a clinical-stage biopharmaceutical company that develops innovative immunotherapies by harnessing the power of regulatory T cells (Tregs) to treat immune disorders and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
REGiMMUNE Comparables
Compare REGiMMUNE with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Treg Therapeutics | 77% | |
| Swedish Orphan Biovitrum | 77% | |
| COUR Pharmaceuticals | 76% | |
REGiMMUNE Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Sep 22, 2025 | ||||
| Series E | Apr 7, 2017 | ||||
| Series D | Feb 14, 2014 | ||||
| Private Placement | Mar 28, 2012 | ||||
| Series C | Jan 31, 2012 | ||||
Grant | Dec 8, 2008 |
REGiMMUNE Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| JAFCO Group Co., Ltd. | Series A |
| Shinkin Capital Co., Ltd. | Series C |
| Mizuho Capital | Series D |
| Yasuda Enterprise Development | Series A, Series B |
| Oita Venture Capital Co., Ltd. | Series E |
| Daiwa Corporate Investment Co., Ltd. | Series B |
| WHIZ Partners, Inc. | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 14, 2026
Monthly visitors increased 51% MoM.
- Sep 22, 2025
$10.26M round led by BioPhoenix Co., Ltd.
REGiMMUNE Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about REGiMMUNE's valuation, stock price, and market status.